These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11117919)

  • 21. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC
    Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab.
    Ljung T; Staun M; Grove O; Fausa O; Vatn MH; Hellström PM
    Scand J Gastroenterol; 2002 Sep; 37(9):1108-10. PubMed ID: 12374238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab.
    Thiebault H; Boyard-Lasselin P; Guignant C; Guillaume N; Wacrenier A; Sabbagh C; Rebibo L; Brazier F; Meynier J; Nguyen-Khac E; Dupas JL; Goëb V; Fumery M
    Eur J Gastroenterol Hepatol; 2016 Aug; 28(8):876-81. PubMed ID: 27101404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gut inflammation and spondyloarthropathies.
    De Keyser F; Baeten D; Van den Bosch F; De Vos M; Cuvelier C; Mielants H; Veys E
    Curr Rheumatol Rep; 2002 Dec; 4(6):525-32. PubMed ID: 12427369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms in failure of infliximab for Crohn's disease.
    Nikolaus S; Raedler A; Kühbacker T; Sfikas N; Fölsch UR; Schreiber S
    Lancet; 2000 Oct; 356(9240):1475-9. PubMed ID: 11081530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
    Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease.
    Izbéki F; Nagy F; Szepes Z; Kiss I; Lonovics J; Molnár T
    Inflamm Bowel Dis; 2008 Mar; 14(3):429-31. PubMed ID: 17973302
    [No Abstract]   [Full Text] [Related]  

  • 31. Systemic amyloidosis with Crohn's disease treated with infliximab.
    Park YK; Han DS; Eun CS
    Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment outcome of spondyloarthropathy with infliximab].
    Głowska A; Wiland P; Szechiński J
    Pol Arch Med Wewn; 2005 Jan; 113(1):42-7. PubMed ID: 16130600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Intestines and joints: an entity?].
    De Vos M
    Verh K Acad Geneeskd Belg; 2002; 64(2):85-99; discussion 99-104. PubMed ID: 12085568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D; Claudepierre P; Lohse A; Toussirot E; Breban M
    Presse Med; 2003 Oct; 32(32):1517-24. PubMed ID: 14534471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
    Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
    Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease.
    Herfarth H; Obermeier F; Andus T; Rogler G; Nikolaus S; Kuehbacher T; Schreiber S
    Am J Gastroenterol; 2002 Oct; 97(10):2688-90. PubMed ID: 12385472
    [No Abstract]   [Full Text] [Related]  

  • 38. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab.
    Simón JA; Burgos-Vargas R
    Dermatology; 2008; 216(3):234-5. PubMed ID: 18182816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-TNF-alpha treatment and spondyloarthropathies].
    Braun Y; Balbir-Gurman A
    Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demyelination-like syndrome in Crohn's disease after infliximab therapy.
    Freeman HJ; Flak B
    Can J Gastroenterol; 2005 May; 19(5):313-6. PubMed ID: 15915246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.